FDA approved a new breakthrough therapy for Cystic Fibrosis
USA Food and Drug Agency (FDA) approved Trikafta (elexacaftor / ivacaftor / tezacaftor), a first triple-combination therapy, which will be available for treatment of patients with the most common mutation in cystic fibrosis (CF). Trikafta was approved for patients at 12 years of age, or more, who have at least one copy of F508del mutation…